International Nonproprietary Generic Name of the medication – rimonabant
Brand Name – Acomplia
Acomplia with main component rimonabant is belongs to the therapeutic agents called Cannabinoid-1 Receptor Blockers CB1. The drug is intended for obesity treatment by reducing appetite.
The drug is produced by Sanofi-Aventis Company. Acomplia is approved for marketing in the European Union since 2006. Still the drug is not approved for use in the United States.
Acomplia works by selectively blocking CB1 receptors in the brain and in peripheral organs important in glucose and lipid metabolism.
Acomplia blocks the same brain parts that make people feel hungry when they smoke hemp plant.
CB1 receptor acts to lessen the activity of the endocannabinoid system (EC system) which plays an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
Acomplia is indicated as a complementary to diet and exercise to treat obese or overweight patients. It is use for patients with Type 2 diabetes and extra amounts of fat in the blood.
The other indication of Acomplia as the manufacturer claims is the treatment of smoking cessation.
Side effects of Acomplia in obesity are:
Before using this drug consult your doctor to eliminate all the possible risks for your health.